A detailed history of Manchester Capital Management LLC transactions in Biogen Inc. stock. As of the latest transaction made, Manchester Capital Management LLC holds 908 shares of BIIB stock, worth $143,373. This represents 0.02% of its overall portfolio holdings.

Number of Shares
908
Previous 901 0.78%
Holding current value
$143,373
Previous $208,000 15.38%
% of portfolio
0.02%
Previous 0.03%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 05, 2024

BUY
$189.07 - $236.8 $1,323 - $1,657
7 Added 0.78%
908 $176,000
Q2 2024

Aug 08, 2024

SELL
$190.52 - $236.72 $1,143 - $1,420
-6 Reduced 0.66%
901 $208,000
Q1 2024

May 06, 2024

BUY
$212.02 - $267.71 $15,689 - $19,810
74 Added 8.88%
907 $195,000
Q4 2023

Feb 08, 2024

BUY
$222.59 - $267.94 $3,784 - $4,554
17 Added 2.08%
833 $215,000
Q3 2023

Nov 09, 2023

BUY
$253.3 - $285.89 $37,995 - $42,883
150 Added 22.52%
816 $209,000
Q1 2022

May 09, 2022

SELL
$193.77 - $244.14 $3,875 - $4,882
-20 Reduced 2.92%
666 $140,000
Q4 2021

Feb 10, 2022

BUY
$223.92 - $287.77 $3,582 - $4,604
16 Added 2.39%
686 $165,000
Q1 2021

May 13, 2021

SELL
$242.95 - $284.63 $22,108 - $25,901
-91 Reduced 11.96%
670 $187,000
Q4 2020

Feb 16, 2021

BUY
$236.26 - $355.63 $21,027 - $31,651
89 Added 13.24%
761 $186,000
Q3 2020

Oct 27, 2020

SELL
$264.77 - $305.71 $379,944 - $438,693
-1,435 Reduced 68.11%
672 $191,000
Q1 2020

May 14, 2020

BUY
$268.85 - $341.04 $41,402 - $52,520
154 Added 7.89%
2,107 $667,000
Q4 2019

Feb 10, 2020

SELL
$220.06 - $304.07 $25,526 - $35,272
-116 Reduced 5.61%
1,953 $580,000
Q2 2019

Aug 05, 2019

SELL
$219.29 - $241.72 $15,350 - $16,920
-70 Reduced 3.27%
2,069 $484,000
Q1 2019

May 08, 2019

BUY
$216.71 - $338.96 $40,308 - $63,046
186 Added 9.52%
2,139 $506,000
Q3 2017

Nov 09, 2017

BUY
$281.15 - $329.69 $549,085 - $643,884
1,953
1,953 $612,000

Others Institutions Holding BIIB

About BIOGEN INC.


  • Ticker BIIB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 144,000,992
  • Market Cap $22.7B
  • Description
  • Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
More about BIIB
Track This Portfolio

Track Manchester Capital Management LLC Portfolio

Follow Manchester Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Manchester Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Manchester Capital Management LLC with notifications on news.